HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks.
about
Contribution of CXCL12 secretion to invasion of breast cancer cells.Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domainIQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistanceTargeted therapies with companion diagnostics in the management of breast cancer: current perspectivesProgress toward overcoming hypoxia-induced resistance to solid tumor therapySurfing the Protein-Protein Interaction Surface Using Docking Methods: Application to the Design of PPI InhibitorsCytosolic phospholipase A2 activation correlates with HER2 overexpression and mediates estrogen-dependent breast cancer cell growth.Phage display in molecular imaging and diagnosis of cancer.A conformationally constrained peptidomimetic binds to the extracellular region of HER2 proteinCharacterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells.Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2Trastuzumab-induced cardiac dysfunction: A 'dual-hit'Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast CancerTrastuzumab has preferential activity against breast cancers driven by HER2 homodimers.Medicinal chemistry for 2020Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic.HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate designStructure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3.Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas.Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis.Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy.Defining what matters most to patients.Improving patient care: expert nursing and service development.Current treatment of HER 2+ metastatic breast cancer.Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance.
P2860
Q22000754-93C78480-B1CF-4817-AEE4-43A71BED7FD1Q24293331-AA12AE3F-7815-43AC-A30E-266F42C34085Q24309891-1C02ED47-460F-4A3B-B68D-B90077AF8E24Q26768119-E96A7705-CFE1-46FC-9749-690E178A8870Q26796405-091B8F11-7E4B-41A9-A3D4-CE52C4123933Q26823990-E57E8493-6042-4362-B33E-D9FFA529034BQ30352693-325CB2AE-97DC-4D10-878E-B55C9B601937Q33532734-DEC740C5-A85B-4A4B-B279-4CF2CC66DC05Q34422576-1485EF9D-7358-44A8-BF94-4D1694AD2F6FQ34475414-7B8D265B-B16E-47B7-8556-B7968FC2A73BQ35273305-563ED586-0A40-457A-AA98-0353A91CAC5FQ35532125-675D7EDC-D5D4-41D1-AC7C-57CE60525CAFQ35533514-BA498604-960E-4263-9732-65FD49A89C84Q35566231-0DF335E8-E431-4E70-ABAD-5E1A12C9E1CCQ35593223-504011CF-EC73-4BA9-9500-5DBC66352787Q36610755-789EA21D-8ECC-405D-B22E-D91A760ADBFBQ37698925-C619B652-E9D7-41CC-9150-9305A6EBFB46Q37721805-26DCB689-D9C2-4FC8-8261-21738C6D83CFQ38288965-7B613C5A-63AD-464E-8301-B8FF0CD4498EQ38849205-0BA34551-4990-401C-9424-36915D37DA96Q42109090-1188A55F-07EE-4022-AF4C-1FC90726F793Q47665955-90836050-B164-487D-BBFB-97426A3EAFB9Q49581531-1B7F39B1-4C5B-4E3A-AFB0-79F6E8215BBBQ49581539-8015033B-B01A-4C42-A050-EAF9C61CF348Q55071512-6AFC61E6-6E26-4E6A-B781-F629DDE6AA67
P2860
HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
HER2 therapy. HER2 (ERBB2): fu ...... lly conserved building blocks.
@ast
HER2 therapy. HER2 (ERBB2): fu ...... lly conserved building blocks.
@en
type
label
HER2 therapy. HER2 (ERBB2): fu ...... lly conserved building blocks.
@ast
HER2 therapy. HER2 (ERBB2): fu ...... lly conserved building blocks.
@en
prefLabel
HER2 therapy. HER2 (ERBB2): fu ...... lly conserved building blocks.
@ast
HER2 therapy. HER2 (ERBB2): fu ...... lly conserved building blocks.
@en
P2860
P921
P356
P1476
HER2 therapy. HER2 (ERBB2): fu ...... lly conserved building blocks.
@en
P2093
Ralf Landgraf
P2860
P2888
P356
10.1186/BCR1633
P577
2007-01-01T00:00:00Z
P5875
P6179
1036067027